How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact

• Dobromir T. Dimitrov ,

  * E-mail: ddimitro@fredhutch.org

  Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, Department of Applied Mathematics, University of Washington, Seattle, Washington, United States of America

  ⨯
• Marie-Claude Boily,

  Affiliation Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom

  ⨯
• Timothy B. Hallett,

  Affiliation Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom

  ⨯
• Jan Albert,

  Affiliations Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden, Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden

  ⨯
• Charles Boucher,

  Affiliation Department of Virology, Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, Netherlands

  ⨯
• John W. Mellors,

  Affiliation Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Deenan Pillay,

  Affiliation Research Department of Infection, University College Medical School, London, United Kingdom

  ⨯
• David A. M. C. van de Vijver

  Affiliation Department of Virology, Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, Netherlands

  ⨯